This retrospective study was carried out at King Abdulaziz University Hospital and King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia, which are 2 main referral hospitals in the western region of Saudi Arabia. Inclusion criteria included all cases diagnosed as kidney lymphoma between January 2002 and April 2022. The project started in January 2022 and was completed in August 2022. Exclusion criteria included cases with no available pathology slides and paraffin blocks. The definition proposed by Krol et al11 (link)
was used to define primary extranodal NHL, which includes all patients who present with NHL originating at the kidney, even in the presence of disseminated disease, if the kidney component is clinically dominant.
The collected clinical data included age at presentation, gender, clinical features, and treatment. The immunohistochemistry slides were reviewed, and more immunohistochemistry markers were added in selected cases. The minimum immunohistochemistry panel included CD45, CD20, CD3, BCL-2, BCL-6, CD10, MUM-1, and KI-67. Additional panels were added in selected cases and included CD21, CD23, CD30, CD79a, CD38, CD138, Fascin, PAX-5, CD15, Epstein-Barr virus (EBV), and pankeratin. The additional panel was carried out to confirm subtype, to rule out Hodgkin lymphoma and viral inclusions. Histopathological classification of lymphomas was according to the 2017 World Health Organization (WHO) criteria.12
Diffuse large B-cell lymphomas were subclassified according to Hans algorithm to germinal center B-cells (GCB) and non-GCB which depends on the pattern of immunohistochemical expression for CD10, MUM-1, and BCL-6.13 (link)
The study was approved by the Research Committee of the Biomedical Ethics Unit at King Abdulaziz University, Jeddah, Saudi Arabia (reference no.: 34-22). The study was carried out according to the principles of Helsinki Declaration. A review of morphology and additional immunohistochemistry markers allowed the re-classification of older cases into currently accepted diagnostic categories.
was used to define primary extranodal NHL, which includes all patients who present with NHL originating at the kidney, even in the presence of disseminated disease, if the kidney component is clinically dominant.
The collected clinical data included age at presentation, gender, clinical features, and treatment. The immunohistochemistry slides were reviewed, and more immunohistochemistry markers were added in selected cases. The minimum immunohistochemistry panel included CD45, CD20, CD3, BCL-2, BCL-6, CD10, MUM-1, and KI-67. Additional panels were added in selected cases and included CD21, CD23, CD30, CD79a, CD38, CD138, Fascin, PAX-5, CD15, Epstein-Barr virus (EBV), and pankeratin. The additional panel was carried out to confirm subtype, to rule out Hodgkin lymphoma and viral inclusions. Histopathological classification of lymphomas was according to the 2017 World Health Organization (WHO) criteria.12
Diffuse large B-cell lymphomas were subclassified according to Hans algorithm to germinal center B-cells (GCB) and non-GCB which depends on the pattern of immunohistochemical expression for CD10, MUM-1, and BCL-6.13 (link)
The study was approved by the Research Committee of the Biomedical Ethics Unit at King Abdulaziz University, Jeddah, Saudi Arabia (reference no.: 34-22). The study was carried out according to the principles of Helsinki Declaration. A review of morphology and additional immunohistochemistry markers allowed the re-classification of older cases into currently accepted diagnostic categories.
Free full text: Click here
